HOME >> BIOLOGY >> NEWS
Three Pacific Northwest National Laboratory inventions win R&D 100 Awards

RICHLAND, Wash.--Three Pacific Northwest National Laboratory inventions have made the 2003 list of the world's 100 most important scientific and technical innovations, according to an annual competition by R&D Magazine. This brings the PNNL R&D 100 Awards total to 62 since the contest's inception in 1969, 55 of them since 1988.

The Department of Energy laboratory was recognized for PASS, a handheld tool that enlists ultrasound pulses to assay the contents of sealed containers without having to open them; for Starlight, an information visualization system--software that graphically depicts connections among disparate pieces of information from large, complex and dynamic collections; and for FT-MS Proteome Express, an instrument that may trim years off the time required to analyze a proteome, or the entire protein set of an organism.

Customs inspectors and international border agents are using the PNNL-developed Acoustic Inspection Device to identify contents within sealed containers. (6"x4" 300 dpi image available from PNNL's Photo Library ).

PASS, or Product Acoustic Signature System, works by bouncing sound off a container's contents, then collecting a telltale echo from what's inside. An official can run PASS, which looks like a power drill crossed with a blow-dryer, over a tanker truck or barrel to distinguish crude oil from vegetable oil or chemical weapons agents. The device can also unmask hidden packages, reveal secret compartments and determine a container's fill level. PASS can save time and protect law enforcement and border inspectors from potentially hazardous materials. Aaron Diaz, PNNL senior research scientist, led the development of the PASS technology, which is licensed to Mehl, Griffin, & Bartek Ltd. of Crystal City, Va. MGB shares the award.

Starlight was originally developed for the U.S. intelligence community to identify terrorist threats. That same technology can elicit relationships in a diverse array of a
'"/>

Contact: Greg Koller
greg.koller@pnl.gov
509-372-4864
DOE/Pacific Northwest National Laboratory
21-Jul-2003


Page: 1 2 3

Related biology news :

1. Three new South American fish identified
2. Three personal ads for physics
3. Three molecular-targeted compounds show promise against cancers
4. Three genes linked to psoriasis susceptibility identified on chromosome 17
5. Three Gorges Dam is an opportunity for ecoscience
6. Three tourist experiences named best worldwide for environmental, social responsibility
7. Three inferior prefrontal regions of the brain found receptive to somatosensory stimuli
8. Three dimensional structure of a protein transport machine
9. Three studies released this week shed new light on eating nuts for good health
10. Three nations agree to share ice core thatmay yield clues about nature of Lake Vostok
11. Three-D images shed light on first steps of RNA synthesis

Post Your Comments:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
Cached News: